HOME > TOP STORIES
TOP STORIES
-
REGULATORY 16 Possible Topics for New Guidelines Including Continuous Manufacturing to Be Discussed at First ICH “Interim Meeting” this Week
March 26, 2018
-
BUSINESS Lilly Japan Sales Up 7% in 2017, Upbeat Biz Fueled by Global Simultaneous Development
March 23, 2018
-
BUSINESS Single Generic Pricing Rule Will Accelerate Unreasonable Price Raises: Sawai Chief
March 22, 2018
-
BUSINESS Toho to Thoroughly Implement Drug Distribution GL, Focus on Cost-Cutting in Response to Impact of Drug Pricing Reform: Pres.
March 20, 2018
-
REGULATORY MHLW Health Policy Chief Questions Volume-Focused Sales Strategies, Urges Drug Makers to Shift to Healthy Lifespan Extension
March 19, 2018
-
BUSINESS Shionogi Nabs Rights to Osaka Upstart’s Tissue Regeneration-Inducing Peptide
March 16, 2018
-
BUSINESS Japan Likely the Only Negative Growth Pharma Market in 2018-2022: IQVIA
March 16, 2018
-
BUSINESS Shionogi’s Single-Dose Flu Med Xofluza Hits Japan Shelves
March 15, 2018
-
BUSINESS Gilead Japan Rolling Up Its Sleeves for Foray into Oncology/Inflammation Market
March 14, 2018
-
TRENDS Merck Deal Could Pave Way for Eisai to Hit 800 Billion Yen Sales Target in FY2020
March 13, 2018
-
BUSINESS Eisai Bags Up-to-US$5.76 Billion Lenvima Alliance with Merck
March 9, 2018
-
BUSINESS Foreign Drug Makers Increased Market Share to Over 60% among Top 20 Makers in 2017
March 9, 2018
-
BUSINESS Torii’s Futhan to Get 43.4% Price Cut in April, Urinorm 24.6%: Top 5 Product Survey
March 8, 2018
-
BUSINESS Mid-Sized Japan Makers to Take Heaviest Hit from April Price Cut, Bigger Peers See Smaller Reductions: Jiho Survey
March 7, 2018
-
REGULATORY Winners and Losers of New PMP Criteria: Januvia Earns 1st Premium while Xarelto, Humira Miss It
March 6, 2018
-
REGULATORY 314 APIs Eligible for Price Maintenance Premium in FY2018, Down from 416
March 5, 2018
-
REGULATORY Opdivo Faces 23.8% Price Cut as Slew of Reduction Rules Apply; Nexium Down 16.1% on Huge Seller Slash
March 5, 2018
-
BUSINESS Japan Ethical Drug Sales Slip 1.0% in 2017, Harvoni Drops Out of Top 10 List: IQVIA
March 2, 2018
-
BUSINESS Despite Solid Mainstays, Pfizer Japan’s FY2017 Sales Down 6.6% on LLPs
March 2, 2018
-
ACADEMIA Nephrology Society Compiles New Drug Development Guidelines for Advanced CKD; Will Guidelines for Early-Stage CKD Follow?
March 1, 2018
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
